<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Alcohol withdrawal: Ambulatory management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Alcohol withdrawal: Ambulatory management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Alcohol withdrawal: Ambulatory management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen R Holt, MD, MS, FACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeanette M Tetrault, MD, FACP, FASAM</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Murray B Stein, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Friedman, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 06, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H699365771"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Individuals with alcohol use disorder may experience a withdrawal syndrome when they abruptly stop or sharply reduce consumption of alcohol. In some cases, these can progress to life threatening seizures or delirium tremens (DT). The goals of medically supervised withdrawal are to alleviate withdrawal symptoms, prevent worsening symptoms, and to prepare the individual for transition to the maintenance phase of treatment (ie, treatment of alcohol use disorder). (See  <a class="medical medical_review" href="/z/d/html/108527.html" rel="external">"Alcohol withdrawal: Epidemiology, clinical manifestations, course, assessment, and diagnosis"</a>.)</p><p>Medically supervised alcohol withdrawal is indicated for patients with current symptoms of withdrawal or at risk of developing alcohol withdrawal. For many individuals with mild symptoms and no history of seizures or DT, supervised withdrawal can be safely and effectively managed in the ambulatory setting. Ambulatory management of alcohol withdrawal is reviewed here.</p><p>Individuals with more severe symptoms of withdrawal, or at risk for developing severe symptoms such as delirium or seizures require closer monitoring, typically in an inpatient setting. Management of individuals with moderate to severe withdrawal is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/323.html" rel="external">"Management of moderate and severe alcohol withdrawal syndromes"</a>.)</p><p>Other topics related to alcohol use and alcohol withdrawal are found elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7809.html" rel="external">"Risky drinking and alcohol use disorder: Epidemiology, clinical features, adverse consequences, screening, and assessment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/108891.html" rel="external">"Alcohol use disorder: Treatment overview"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7800.html" rel="external">"Alcohol use disorder: Pharmacologic management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7810.html" rel="external">"Alcohol use disorder: Psychosocial management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14843.html" rel="external">"Screening for unhealthy use of alcohol and other drugs in primary care"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/108527.html" rel="external">"Alcohol withdrawal: Epidemiology, clinical manifestations, course, assessment, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/323.html" rel="external">"Management of moderate and severe alcohol withdrawal syndromes"</a>.)</p><p></p><p class="headingAnchor" id="H470181813"><span class="h1">ALCOHOL WITHDRAWAL: DIAGNOSIS AND NEED FOR TREATMENT</span><span class="headingEndMark"> — </span>We initiate management of alcohol withdrawal on most individuals with alcohol use disorder who have recently discontinued or sharply reduced their consumption. Exceptions include individuals who have been drinking for four weeks or less and those that exclusively binge drink three times or less per week. These individuals have an extremely low likelihood of alcohol withdrawal and typically do not warrant supervised withdrawal. For such patients, we encourage clinicians to instead assess for alcohol use disorder and consider treatment for it. The diagnosis of alcohol use disorder and its treatments are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7809.html" rel="external">"Risky drinking and alcohol use disorder: Epidemiology, clinical features, adverse consequences, screening, and assessment", section on 'Binge drinking'</a> and  <a class="medical medical_review" href="/z/d/html/108891.html" rel="external">"Alcohol use disorder: Treatment overview"</a> and  <a class="medical medical_review" href="/z/d/html/7800.html" rel="external">"Alcohol use disorder: Pharmacologic management"</a> and  <a class="medical medical_review" href="/z/d/html/7810.html" rel="external">"Alcohol use disorder: Psychosocial management"</a>.)</p><p>Symptoms of alcohol withdrawal typically begin within 6 to 24 hours of the last drink or sudden reduction in chronic alcohol use [<a href="#rid1">1-4</a>]. If withdrawal does not progress, symptoms generally resolve within 24 to 48 hours, often sooner. It is estimated that half of the individuals with moderate to severe alcohol use disorder experience withdrawal symptoms upon stopping or sharply reducing their intake [<a href="#rid1">1,3</a>]. The manifestations, assessment, diagnosis, and course of alcohol withdrawal can be found elsewhere  (<a class="graphic graphic_table graphicRef75499" href="/z/d/graphic/75499.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/108527.html" rel="external">"Alcohol withdrawal: Epidemiology, clinical manifestations, course, assessment, and diagnosis"</a>.)</p><p class="headingAnchor" id="H3669876741"><span class="h1">CANDIDACY FOR AMBULATORY MANAGEMENT</span><span class="headingEndMark"> — </span>For all individuals who have been assessed for and found to need treatment for alcohol withdrawal, we start by confirming that they are appropriate candidates for treatment in the ambulatory setting. We do this in two steps: first, we assess for contraindications to ambulatory management. If none exist, we further assess for complex comorbidities, unstable psychosocial factors, and pregnancy all of which might impact our decision.</p><p class="headingAnchor" id="H4256607755"><span class="h2">Contraindications to ambulatory management</span><span class="headingEndMark"> — </span>We consider a prior history of withdrawal delirium or seizures or a current symptom severity of modest or greater (ie, Clinical Institute Withdrawal Assessment for Alcohol, Revised [CIWA-Ar] score &gt;15) to be contraindications to ambulatory management of alcohol withdrawal. (See <a class="local">'History of withdrawal delirium or seizures'</a> below and <a class="local">'Modest or severe symptom severity'</a> below.)</p><p class="headingAnchor" id="H2242969175"><span class="h3">History of withdrawal delirium or seizures</span><span class="headingEndMark"> — </span>We do not manage individuals with a prior history of withdrawal delirium or alcohol withdrawal seizure in the ambulatory setting. A prior history of either delirium tremens (DT) or a prior seizure related to alcohol withdrawal appears to predict a similar occurrence in future episodes. We consider these individuals to have a high risk for severe withdrawal complications. (See  <a class="medical medical_review" href="/z/d/html/323.html" rel="external">"Management of moderate and severe alcohol withdrawal syndromes"</a>.)</p><p>In a meta-analysis of six studies including 1637 subjects, individuals with a prior history of DT had a greater likelihood of recurrent DT as compared with individuals without a history of DT (odds ratio 2.6, 95% CI 1.4-4.7) [<a href="#rid1">1</a>]. Additionally, in two studies including 1143 subjects, individuals with a history of withdrawal seizures had a greater likelihood of recurrence of withdrawal seizures as compared with individuals without a prior history (odds ratio 2.8, 95% CI 1.1-7.2).</p><p class="headingAnchor" id="H3969912877"><span class="h3">Modest or severe symptom severity</span><span class="headingEndMark"> — </span>We confirm the individual’s current level of symptoms is no higher than mild (ie, CIWA-Ar ≤15). We do this by administering the 10-question CIWA-Ar [<a href="#rid5">5,6</a>]. The CIWA-Ar scale and scoring parameters are on the table  (<a class="graphic graphic_table graphicRef64835" href="/z/d/graphic/64835.html" rel="external">table 2</a>) (<a class="calc calc_professional" href="/z/d/html/13437.html" rel="external">calculator 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>We refer individuals with a CIWA-Ar score of &gt;15 (ie, modest or severe withdrawal) for inpatient treatment. We do not consider individuals with a score of &gt;15 to be candidates for ambulatory withdrawal. (See  <a class="medical medical_review" href="/z/d/html/323.html" rel="external">"Management of moderate and severe alcohol withdrawal syndromes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We consider individuals with CIWA-Ar score of ≤15 (ie, mild or very mild withdrawal) to be potential candidates for ambulatory management.</p><p></p><p class="headingAnchor" id="H1703824177"><span class="h2">Other reasons to avoid ambulatory management</span><span class="headingEndMark"> — </span>If complex comorbidities such as those listed below are not present and if the psychosocial factors are favorable, we treat individuals who are not pregnant in the ambulatory setting.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complex comorbidity</strong> – We manage individuals with complex chronic medical or psychiatric comorbidities in the inpatient setting. There is a lack of consensus about the individual risk factors that consistently contribute to severe alcohol withdrawal. Prediction of alcohol withdrawal is variable and few demographic, clinical, or biochemical parameters are consistently predictive [<a href="#rid1">1,7</a>]. Acute and chronic medical comorbidities can increase the risk of developing a severe alcohol withdrawal syndrome. (See  <a class="medical medical_review" href="/z/d/html/108527.html" rel="external">"Alcohol withdrawal: Epidemiology, clinical manifestations, course, assessment, and diagnosis", section on 'Assessment'</a>.)</p><p></p><p class="bulletIndent1">As examples, we do not treat alcohol withdrawal in the ambulatory setting in individuals with the following comorbidities:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Heart failure – Class II or higher heart failure. (See  <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Decompensated cirrhosis. (See  <a class="medical medical_review" href="/z/d/html/1253.html" rel="external">"Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Individuals with chronic obstructive pulmonary disease who are oxygen dependent. (See  <a class="medical medical_review" href="/z/d/html/1455.html" rel="external">"Chronic obstructive pulmonary disease: Diagnosis and staging"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Kidney disease – Stage IV or higher kidney disease. (See  <a class="medical medical_review" href="/z/d/html/16406.html" rel="external">"Definition and staging of chronic kidney disease in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Epilepsy or history of seizure of any cause.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Recent head injury with loss of consciousness or intracranial hemorrhage.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unstable or active psychiatric illness causing active psychosis, mania, depression, or suicidal ideation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Febrile illness.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Benzodiazepine use disorder – We do not treat individuals with comorbid active benzodiazepine use disorder or a history of benzodiazepine use disorder in the ambulatory setting. These individuals have a higher potential for severe withdrawal symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unfavorable psychosocial factors </strong>– We consider the individual’s ability to accurately monitor and report their symptoms, to take medications as directed, and to attend to all follow-up visits in determining the most appropriate setting for treatment. In cases where the individual is unable to do this, or if we question their ability to do so, we ask a reliable support person (eg, family member) to assist. If this is not possible, we treat the individual in the inpatient setting.</p><p></p><p class="bulletIndent1">In many cases, if the individual or their support is reliable, alternating in-person and remote visits is an acceptable option. If a reliable individual (or an individual with a reliable support) is unable to attend any in-person visits we would consider seeing them through real-time audiovisual/remote means on a case-by-case basis. However, we discourage this option as it is less preferred. We do not treat individuals with no means to get to the appointments and no means for remote visits, or those with cognitive impairment and no supports, in the outpatient setting.</p><p></p><p class="bulletIndent1">As examples, if an individual has cognitive limitations and is without an appropriate support we encourage inpatient treatment. Additionally, if an individual cannot make it to any visits and has no means of contact (eg, no phone, homeless) we treat them in the inpatient setting.</p><p></p><p class="bulletIndent1">We agree to treat individuals in the ambulatory setting if they decline inpatient treatment despite a CIWA-Ar &gt;15. We treat these individuals in the ambulatory setting after a detailed discussion of the risks associated with ambulatory management of moderate or severe withdrawal (eg, seizure, delirium). We discuss these with the individual and the appropriate support. We carefully document the discussion including our preference for inpatient treatment, and the reason the individual declined inpatient treatment (ie, childcare needs, prior negative experiences). We do not withhold treatment for individuals who are withdrawing from alcohol due to inability to engage with treatment setting recommendations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy</strong> – We confirm pregnancy status of all appropriate individuals of childbearing age. We treat all pregnant individuals for alcohol withdrawal in the inpatient setting. (See  <a class="medical medical_review" href="/z/d/html/4799.html" rel="external">"Substance use during pregnancy: Screening and prenatal care"</a>.)</p><p></p><p class="headingAnchor" id="H1833184943"><span class="h1">BENEFITS OF AMBULATORY MANAGEMENT</span><span class="headingEndMark"> — </span>Medically supervised alcohol withdrawal can be safely and effectively administered to appropriately selected individuals in the ambulatory setting [<a href="#rid8">8</a>]. The ambulatory setting appears to be associated with decreased treatment duration and lower cost than inpatient treatment [<a href="#rid9">9-11</a>].</p><p>For example, in retrospective studies totaling more than 1000 individuals, the rates of successful completion of supervised withdrawal in the ambulatory setting were between 82 and 94 percent [<a href="#rid9">9,10</a>]. In one study of 517 individuals with mild to moderate withdrawal, 453 individuals completed the treatment while maintaining abstinence (based on breath alcohol testing) [<a href="#rid10">10</a>]. Additionally, only 25 patients (5 percent) experienced worsening symptoms during treatment and were referred for inpatient treatment.</p><p>In another trial examining the cost and duration of alcohol withdrawal, 164 individuals with mild to moderate symptoms of withdrawal but no recent seizure or impending delirium tremens were randomized to receive either outpatient or inpatient supervised withdrawal followed by initiation of rehabilitation treatment [<a href="#rid11">11</a>]. The mean duration of treatment was shorter for outpatients compared with inpatients (6.5 versus 9.2 days). While more inpatients completed the treatment than outpatients (95 versus 72 percent), at six-month follow-up, similar findings on the 18-item Addiction Severity Index, a measure of functioning related to substance use, was reported. There were no serious medical complications in either group. Costs were greater for inpatients versus outpatients ($3319 to 3665 versus $175 to 388 per patient).</p><p class="headingAnchor" id="H1453127843"><span class="h1">AMBULATORY MANAGEMENT</span><span class="headingEndMark"> — </span>Our preferred choice of medication and method for monitoring individuals in the ambulatory setting are discussed below and on the associated algorithms  (<a class="graphic graphic_algorithm graphicRef138574" href="/z/d/graphic/138574.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef138558" href="/z/d/graphic/138558.html" rel="external">algorithm 2</a>).</p><p class="headingAnchor" id="H2132587876"><span class="h2">Dose regimens and medication dispensing</span><span class="headingEndMark"> — </span>We prefer to treat all individuals in the ambulatory setting with a fixed-dose regimen. Although there is literature suggesting that symptom-triggered management can be implemented in the ambulatory setting, fixed-dose regimens allow for less subjectivity and variability in dose administration and implementing withdrawal scales can be challenging [<a href="#rid12">12,13</a>]. However, overestimating total dose may lead to oversedation and underestimating doses may lead to more withdrawal symptoms.</p><p>For simplicity, we typically tell the patient to begin treatment as soon as they wake up, before they have taken any alcohol.</p><p>Additionally, we give all individuals five doses of medication to take as needed (ie, symptom-triggered doses) for tremulousness, anxiety, diaphoresis, or palpitations that are present or emerge despite the fixed-dose schedule. We provide education concerning the symptoms that should prompt taking an additional dose and the risks that are associated with additional medications. We prescribe the same medication and dose that is being prescribed for each scheduled dose (ie, fixed dose) during days 2 through 4 of their fixed-dose taper. We provide these extra doses in addition to the medications being given for the fixed-dose regimen. We provide five doses of symptom-triggered medication in the four-day taper as in some cases, residual symptoms warrant extending the taper by a day. For example, in an individual who is being treated with <a class="drug drug_general" data-topicid="9243" href="/z/d/drug information/9243.html" rel="external">chlordiazepoxide</a>, we would prescribe 15 tablets of chlordiazepoxide (50 mg each) in a single prescription (10 doses for fixed taper, 5 extra symptom-triggered doses). (See <a class="local">'Choosing among benzodiazepines'</a> below.)</p><p>We occasionally give fewer doses at a time in individuals who may be at risk for incorrectly taking medication. In these individuals we typically give day-to-day dosing and require closer follow-up. In some cases, we avoid day-to-day dosing by asking the support person to hold and administer all doses.</p><p class="headingAnchor" id="H4240637433"><span class="h2">Choosing medication</span><span class="headingEndMark"> — </span>Our choice of medication for treatment of ambulatory withdrawal is based on the current symptom severity as measured by the Clinical Institute Withdrawal Assessment for Alcohol, Revised (CIWA-Ar)  (<a class="graphic graphic_algorithm graphicRef138574" href="/z/d/graphic/138574.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef64835" href="/z/d/graphic/64835.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H827947257"><span class="h3">For mild withdrawal (CIWA-Ar 10 to 15)</span><span class="headingEndMark"> — </span>We prefer to use benzodiazepines rather than other medications such as anticonvulsants (eg, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>) for treatment of mild withdrawal (CIWA-Ar 10 to 15) in the ambulatory setting. Our preference is based on their extensive history of well-documented effectiveness in the treatment of alcohol withdrawal including lessening the occurrence of seizures and delirium [<a href="#rid14">14-19</a>].</p><p class="headingAnchor" id="H3282517714"><span class="h4">Choosing among benzodiazepines</span><span class="headingEndMark"> — </span>We prefer to use long-acting benzodiazepines (such as <a class="drug drug_general" data-topicid="9243" href="/z/d/drug information/9243.html" rel="external">chlordiazepoxide</a> or <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">diazepam</a>) rather than short-acting benzodiazepines (such as <a class="drug drug_general" data-topicid="9726" href="/z/d/drug information/9726.html" rel="external">oxazepam</a>) in the treatment of alcohol withdrawal in the ambulatory setting. Among long-acting benzodiazepines, our choice is based on clinician familiarity with the agent and patient preference.</p><p>We typically use longer-acting agents despite their potential for increased accumulation and decreased clearance in some individuals (ie, liver disease, older adult). Our preference for long-acting benzodiazepines is based on their having the advantage of providing a steady level of symptom control due to their half-life and active metabolites. These allow for a “self-tapering” effect and a smoother decline in plasma level [<a href="#rid20">20</a>]. In principle, this property lessens the chance of breakthrough or rebound withdrawal symptoms. Additionally, the risk of misuse is lower with longer-acting benzodiazepines. Benzodiazepine kinetics and half-life are displayed on the table  (<a class="graphic graphic_table graphicRef69184" href="/z/d/graphic/69184.html" rel="external">table 3</a>).</p><p>However, based on indirect comparisons there is no strong evidence that any one particular benzodiazepine is more effective than any other in the treatment of alcohol withdrawal [<a href="#rid14">14</a>].</p><p>For <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">diazepam</a> our four-day taper is as follows:</p><p class="bulletIndent2"><span class="glyph">•</span>Day 1: 10 mg orally every 6 hours (40 mg total daily dose)</p><p class="bulletIndent2"><span class="glyph">•</span>Day 2: 10 mg orally every 8 hours (30 mg total daily dose)</p><p class="bulletIndent2"><span class="glyph">•</span>Day 3: 10 mg orally every 12 hours (20 mg total daily dose)</p><p class="bulletIndent2"><span class="glyph">•</span>Day 4: 10 mg once at night (10 mg total daily dose)</p><p></p><p>For <a class="drug drug_general" data-topicid="9243" href="/z/d/drug information/9243.html" rel="external">chlordiazepoxide</a> our taper is as follows:</p><p class="bulletIndent2"><span class="glyph">•</span>Day 1: 50 mg orally every 6 hours (200 mg total daily dose)</p><p class="bulletIndent2"><span class="glyph">•</span>Day 2: 50 mg orally every 8 hours (150 mg total daily dose)</p><p class="bulletIndent2"><span class="glyph">•</span>Day 3: 50 mg orally every 12 hours (100 mg total daily dose)</p><p class="bulletIndent2"><span class="glyph">•</span>Day 4: 50 mg once at night (50 mg total daily dose)</p><p></p><p>Our preferred regimen is shown on the associated algorithm  (<a class="graphic graphic_algorithm graphicRef138574" href="/z/d/graphic/138574.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H2336566948"><span class="h4">Misuse and adverse effects</span><span class="headingEndMark"> — </span>We are cautious about the use of benzodiazepines for ambulatory management of alcohol withdrawal. Benzodiazepines are subject to risks of misuse and development of physiologic dependence, particularly with shorter-acting benzodiazepines or <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">diazepam</a> (due to rapid onset). Additionally, symptomatic withdrawal can occur if benzodiazepines are abruptly stopped [<a href="#rid21">21,22</a>]. This is a particular consideration if shorter-acting benzodiazepines are used. (See <a class="local">'Choosing among benzodiazepines'</a> above.)</p><p>Benzodiazepines can induce respiratory depression, especially if taken in excessive amounts or if combined with other central nervous system depressants, including alcohol. (See  <a class="medical medical_review" href="/z/d/html/88407.html" rel="external">"Benzodiazepine use disorder"</a> and  <a class="medical medical_review" href="/z/d/html/314.html" rel="external">"Benzodiazepine poisoning"</a>.)</p><p class="headingAnchor" id="H2322610216"><span class="h4">Data supporting use of benzodiazepines</span><span class="headingEndMark"> — </span>Benzodiazepines are effective in reducing withdrawal symptoms compared with placebo [<a href="#rid14">14,18,19,23</a>].</p><p>As examples, in a meta-analysis of three trials including 324 individuals with symptoms of alcohol withdrawal, individuals treated with benzodiazepines had a decreased incidence of withdrawal-related seizures versus individuals treated with placebo (relative risk 0.16, 95% CI 0.04-0.69) [<a href="#rid14">14</a>]. In another meta-analysis of three trials including 112 individuals with alcohol withdrawal symptoms, individuals treated with benzodiazepines showed greater reductions in CIWA-Ar scores within the first two days of treatment than individuals treated with placebo (odds ratio 3.28, 95% CI 1.3-8.28) [<a href="#rid18">18</a>].</p><p>Studies comparing the efficacy and safety of individual benzodiazepines in the treatment of alcohol withdrawal have been inconclusive. For example, a meta-analysis comparing the efficacy and safety of individual benzodiazepines for outcomes such as withdrawal seizures, withdrawal delirium, and global assessment of efficacy measures did not report meaningful differences between them [<a href="#rid14">14</a>]. However, trends toward greater efficacy were noted for <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">diazepam</a> versus <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> in the prevention of delirium [<a href="#rid24">24</a>] and <a class="drug drug_general" data-topicid="9243" href="/z/d/drug information/9243.html" rel="external">chlordiazepoxide</a> versus <a class="drug drug_general" data-topicid="8453" href="/z/d/drug information/8453.html" rel="external">alprazolam</a> for prevention withdrawal seizures [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H1745380871"><span class="h3">Very mild withdrawal (CIWA-Ar &lt;10)</span><span class="headingEndMark"> — </span>We prefer to treat individuals with very mild symptoms of alcohol withdrawal (ie, CIWA-Ar &lt;10) with an anticonvulsant medication rather than a benzodiazepine  (<a class="graphic graphic_algorithm graphicRef138574" href="/z/d/graphic/138574.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H1447418600"><span class="h4">Gabapentin as first choice for very mild withdrawal</span><span class="headingEndMark"> — </span>Our preference is to treat individuals with very mild withdrawal (CIWA-Ar &lt;10) with <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> rather than benzodiazepines (or other anticonvulsants). However, for individuals being treated with gabapentin for another indication we typically use a benzodiazepine.</p><p>Our preference for treatment of individuals with very mild withdrawal (CIWA-Ar &lt;10) with <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> is based on the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Established efficacy in appropriately screened individuals</strong> – <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">Gabapentin</a> has been shown to have efficacy comparable to benzodiazepines for reducing symptoms of alcohol withdrawal (other than seizures or the development of delirium tremens [DT]) in the outpatient setting (see <a class="local">'Data supporting use of gabapentin'</a> below). Seizures and DT are relatively rare events in individuals appropriately screened to undergo supervised withdrawal in the ambulatory setting. As an example, an observational study described the supervised withdrawal of 1024 individuals with chronic alcohol use who were referred for ambulatory “detoxification” [<a href="#rid26">26</a>]. The treatment utilized only behavior approaches and no psychoactive medications. Twelve individuals (1.2 percent) experienced seizures and a single patient (0.1 percent) developed DT.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">Gabapentin</a>, as an anticonvulsant, is believed to counteract the “kindling process” that can occur with repeated episodes of alcohol withdrawal. The kindling hypothesis proposes that long-term alcohol dependence and repeated episodes of withdrawal may cause neuronal and neurochemical changes in the brain which leads to an intensification of alcohol withdrawal symptoms with each successive episode [<a href="#rid20">20,27,28</a>]. (See  <a class="medical medical_review" href="/z/d/html/108527.html" rel="external">"Alcohol withdrawal: Epidemiology, clinical manifestations, course, assessment, and diagnosis", section on 'Withdrawal seizures'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Favorable side effect profile </strong>– <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">Gabapentin</a> is associated with less sedation [<a href="#rid29">29,30</a>], and in our clinical experience, less cognitive and psychomotor impairment than benzodiazepines.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lower potential for misuse and the development of addiction</strong> – There are no data directly comparing rates of misuse between <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> and benzodiazepines. Based on the limited data available, and in our clinical experience, while still potentially a medication that is subject to misuse, gabapentin is less subject to misuse than benzodiazepines for individuals treated for substance use disorder [<a href="#rid31">31-35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy in treatment of alcohol use disorder</strong> – <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">Gabapentin</a> is a favorable choice for treatment of very mild alcohol withdrawal when the clinician plans to use it as maintenance in the treatment of alcohol use disorder. Efficacy of gabapentin in the treatment of alcohol use disorder is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7800.html" rel="external">"Alcohol use disorder: Pharmacologic management", section on 'Gabapentin'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ease of use versus comparable anticonvulsant (ie, </strong><strong>carbamazepine</strong><strong>) </strong>–<strong> </strong>We prefer to use <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> over the anticonvulsant <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> in the treatment of very mild alcohol withdrawal. Gabapentin, as compared with carbamazepine, is associated with fewer drug-drug interactions [<a href="#rid36">36,37</a>] and fewer adverse effects. Additionally, treatment with gabapentin does not require checking of therapeutic levels or other laboratory monitoring and appears to be safe in individuals with impaired liver function [<a href="#rid17">17,36</a>]. (See <a class="local">'Other options for very mild withdrawal (CIWA-Ar &lt;10)'</a> below and  <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects"</a>.)</p><p></p><p class="headingAnchor" id="H834420703"><span class="h5">Gabapentin taper</span><span class="headingEndMark"> — </span>We treat most individuals with very mild withdrawal (CIWA &lt;10) with a <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> taper. Our taper is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Day 1: 300 mg orally every 6 hours (1200 mg total daily dose)</p><p class="bulletIndent1"><span class="glyph">●</span>Day 2: 300 mg orally every 8 hours (900 mg total daily dose)</p><p class="bulletIndent1"><span class="glyph">●</span>Day 3: 300 mg orally every 12 hours (600 mg total daily dose)</p><p class="bulletIndent1"><span class="glyph">●</span>Day 4: 300 mg once at night (300 mg total daily dose)</p><p></p><p>Our preferred regimen is shown on the associated algorithm  (<a class="graphic graphic_algorithm graphicRef138574" href="/z/d/graphic/138574.html" rel="external">algorithm 1</a>).</p><p>In addition, we give five extra tablets to be used for symptom-triggered dosing (see <a class="local">'Dose regimens and medication dispensing'</a> above).</p><p>Side effects of <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> include dizziness, drowsiness, ataxia, diarrhea, weakness, and nausea and vomiting.</p><p class="headingAnchor" id="H2213607203"><span class="h5">Data supporting use of gabapentin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">Gabapentin</a>, a gamma-aminobutyric acid analog, appears to be a safe and effective alternative to benzodiazepines for the treatment of very mild alcohol withdrawal in the ambulatory setting [<a href="#rid29">29,30</a>]. However, based on limited data, it is unclear if anticonvulsants as a group, or gabapentin in particular, provides the same degree of protection against alcohol withdrawal seizures and alcohol-related delirium as benzodiazepines do [<a href="#rid38">38-41</a>].</p><p><a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">Gabapentin</a> may lower craving for alcohol during the course of the treatment while being associated with fewer side effects. As examples, in a clinical trial, 100 individuals with symptoms of alcohol withdrawal (CIWA-Ar ≥10) were randomized to receive one of three different four-day tapers (gabapentin starting at 1200 mg/day, gabapentin starting at 900 mg/day, or <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> starting at 6 mg/day) [<a href="#rid29">29</a>]. Individuals had access to additional symptom-triggered doses of the assigned medication. Withdrawal-symptom severity, as measured by CIWA-Ar, decreased over time in all groups. Over the course of the treatment, individuals in the higher dose gabapentin group (1200 mg) had a lower average CIWA-Ar scale then the lorazepam group (3.1 versus 4.3). Additionally, treatment with either target dose of gabapentin appeared to result in less craving and less anxiety (as measured by the Zung Anxiety Scale) during the treatment period. There was a tendency towards less sedation in individuals in the gabapentin treated group versus those in the lorazepam treated group. Furthermore, individuals in the gabapentin treated groups had a lower probability of drinking during the seven-day follow-up.</p><p>In another trial including 26 individuals with symptoms of alcohol withdrawal (CIWA-Ar &gt;5) individuals were randomized to receive a six day taper of either <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> or <a class="drug drug_general" data-topicid="9243" href="/z/d/drug information/9243.html" rel="external">chlordiazepoxide</a> [<a href="#rid30">30</a>]. CIWA-Ar scales were reduced similarly in both groups. However, at treatment end, individuals treated with gabapentin experienced less daytime sleepiness on the Epworth sleepiness scale (ESS) and a trend towards reduced craving on the Penn Alcohol Craving scale (PACS) than individuals treated with chlordiazepoxide (mean difference ESS -3.7, 95% CI -7.2 to -0.2; mean difference PACS -6.1, 95% CI -12.8 to 0.7).</p><p class="headingAnchor" id="H1390231939"><span class="h4">Other options for very mild withdrawal (CIWA-Ar &lt;10)</span><span class="headingEndMark"> — </span>For individuals with a history of adverse effects to <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> or in whom gabapentin has previously been ineffective, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> is another option for treatment.</p><p class="headingAnchor" id="H380990725"><span class="h5">Carbamazepine</span><span class="headingEndMark"> — </span>We occasionally use <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> for the treatment of very mild withdrawal (CIWA-Ar &lt;10) in individuals that are unable to take or have had adverse effects with <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>.</p><p>While <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> appears to be efficacious in reducing symptoms of alcohol withdrawal, data are insufficient to support its efficacy in preventing withdrawal seizures or delirium [<a href="#rid38">38,42</a>].</p><p>We prescribe <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> at the following doses according to a fixed-dose regimen for all individuals that we are treating for very mild withdrawal. We also give five extra doses for symptom-triggered dosing. (See <a class="local">'Dose regimens and medication dispensing'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>Day 1: <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">Carbamazepine</a> 200 mg orally every 6 hours (800 mg total daily dose)</p><p class="bulletIndent1"><span class="glyph">●</span>Day 2: <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">Carbamazepine</a> 200 mg orally every 8 hours (600 mg total daily dose)</p><p class="bulletIndent1"><span class="glyph">●</span>Day 3: <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">Carbamazepine</a> 200 mg orally every 12 hours (400 mg total daily dose)</p><p class="bulletIndent1"><span class="glyph">●</span>Day 4: <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">Carbamazepine</a> 200 mg orally at night (200 mg total daily dose)</p><p></p><p>In a meta-analysis of three trials (two inpatient, one outpatient) including 262 patients, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> reduced symptoms of alcohol withdrawal (as measured by CIWA-Ar score) similarly compared with benzodiazepines (mean difference -1.04, -1.89 to -0.20) [<a href="#rid38">38</a>]. Additionally, in one trial including 136 individuals with moderate alcohol withdrawal, individuals were randomized to five days taper of either <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> or carbamazepine from comparable initial doses (ie, 600 to 800 mg carbamazepine; 6 to 8 mg lorazepam) [<a href="#rid43">43</a>]. While both treatment arms were effective in reducing alcohol withdrawal symptoms, individuals in the carbamazepine group appeared to have a lower risk of rebound withdrawal symptoms at the conclusion of treatment and a lower risk of return to drinking in the immediate posttreatment period. Clinician-rated side effects (eg, dizziness, incoordination, light-headedness, and drowsiness) were more common in individuals treated with lorazepam compared with those treated with carbamazepine (23 versus 7 percent).</p><p>Due to the need for therapeutic monitoring and the drug-drug interactions associated with <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, we use it for treatment of very mild withdrawal only after a trial of <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>. We are cautious in prescribing carbamazepine due to adverse effects such as blood dyscrasias and hepatotoxicity. Other side effects include dizziness, drowsiness and pruritus [<a href="#rid43">43,44</a>].</p><p>Other options for individuals who cannot take <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> or <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> include long-acting benzodiazepines. (See <a class="local">'Choosing among benzodiazepines'</a> above.)</p><p class="headingAnchor" id="H1597522515"><span class="h5">Medication with limited data to support their use</span><span class="headingEndMark"> — </span>Limited data support the use of the following medications in the treatment of alcohol withdrawal. Further research is needed before their clinical use can be recommended.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oxcarbazepine</strong><strong> </strong>– <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">Carbamazepine</a>’s 10-keto analog, <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">oxcarbazepine</a>, may have equivalent benefits in alcohol withdrawal, with milder side effects and fewer drug interactions [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregabalin</strong><strong>, </strong><strong>levetiracetam</strong><strong>, and </strong><a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproic acid</a> – Data on the safety and efficacy of other anticonvulsants such as <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> [<a href="#rid46">46</a>], <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">levetiracetam</a> [<a href="#rid47">47-49</a>], and valproic acid [<a href="#rid50">50</a>] are insufficient to recommend their use in treating alcohol withdrawal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Baclofen</strong><strong>, </strong><strong>clonidine</strong><strong>, and gamma hydroxy butyrate</strong> – Other medications such as <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">baclofen</a>, <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">clonidine</a>, and gamma hydroxy butyrate have been suggested as being efficacious for the ambulatory treatment of alcohol withdrawal [<a href="#rid16">16,51-54</a>]. However, further studies are needed to confirm their benefits.</p><p></p><p class="headingAnchor" id="H3342808471"><span class="h2">Monitoring in the ambulatory setting</span><span class="headingEndMark"> — </span>An algorithm describes our practice for monitoring individuals being treated for alcohol withdrawal in the ambulatory setting  (<a class="graphic graphic_algorithm graphicRef138558" href="/z/d/graphic/138558.html" rel="external">algorithm 2</a>).</p><p class="headingAnchor" id="H290944647"><span class="h3">Frequency</span><span class="headingEndMark"> — </span>We are in contact with individuals undergoing supervised withdrawal on a daily basis with either in-person or remote visits. We prefer to see all individuals in person daily. We ask the individuals (with the help of their support where needed) to monitor symptoms throughout the day.</p><p class="headingAnchor" id="H3233410308"><span class="h3">Symptom review and scales</span><span class="headingEndMark"> — </span>Prior to initiating treatment, and at each patient contact, whether in-person or remote, we review the symptoms of alcohol withdrawal and ask about the presence or worsening of withdrawal symptoms including:</p><p class="bulletIndent1"><span class="glyph">●</span>Anxiety or nervousness</p><p class="bulletIndent1"><span class="glyph">●</span>Tremor</p><p class="bulletIndent1"><span class="glyph">●</span>Sweating</p><p class="bulletIndent1"><span class="glyph">●</span>Nausea or vomiting</p><p class="bulletIndent1"><span class="glyph">●</span>Auditory, tactile, or visual disturbances</p><p class="bulletIndent1"><span class="glyph">●</span>Headache</p><p class="bulletIndent1"><span class="glyph">●</span>Disorientation</p><p class="bulletIndent1"><span class="glyph">●</span>Agitation</p><p></p><p>If the individual reports an increase in intensity or the emergence of one or more new symptoms either in person or between visits, we ask them to take a single dose of symptom-triggered medication. If symptoms persist, we see them in an in-person visit at the earliest time possible and complete a CIWA-Ar  (<a class="graphic graphic_table graphicRef64835" href="/z/d/graphic/64835.html" rel="external">table 2</a>) (<a class="calc calc_professional" href="/z/d/html/13437.html" rel="external">calculator 1</a>).</p><p class="headingAnchor" id="H648177157"><span class="h3">Individuals needing higher level of care</span><span class="headingEndMark"> — </span>We refer individuals for inpatient treatment (after they have begun treatment in the ambulatory setting) for any of several reasons. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of withdrawal seizure or delirium</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Worsening medical or psychiatric condition (eg, metabolic syndrome, psychosis, mania, suicidal or homicidal ideation)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The individual has used more than one symptom-triggered dose in any 24-hour period to address emergent or worsening symptoms (see <a class="local">'Dose regimens and medication dispensing'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CIWA-Ar increases to &gt;15</p><p></p><p>We refer individuals that are nonadherent to treatment, divert or misuse medication, return to use of alcohol or other substance, to an inpatient or an addiction treatment center.</p><p class="headingAnchor" id="H2189019862"><span class="h2">Nutritional support</span><span class="headingEndMark"> — </span>We offer daily multivitamins with <a class="drug drug_general" data-topicid="9988" href="/z/d/drug information/9988.html" rel="external">thiamine</a> and folate to all individuals being treated for alcohol withdrawal in the ambulatory setting. Individuals with sustained heavy drinking who consume most of their calories from alcohol often develop nutritional deficiencies. Thiamine deficiency is common in this population and can result in Wernicke encephalopathy or Korsakoff syndrome [<a href="#rid27">27,55,56</a>]. (See  <a class="medical medical_review" href="/z/d/html/14614.html" rel="external">"Nutritional status in patients with sustained heavy alcohol use"</a> and  <a class="medical medical_review" href="/z/d/html/4818.html" rel="external">"Wernicke encephalopathy"</a> and  <a class="medical medical_review" href="/z/d/html/4840.html" rel="external">"Overview of the chronic neurologic complications of alcohol"</a>.)</p><p class="headingAnchor" id="H3561412548"><span class="h2">Transition to maintenance treatment for alcohol use disorder</span><span class="headingEndMark"> — </span>We offer explicit plans for follow-up care prior to discharge from the ambulatory treatment setting. We typically refer for ongoing treatment for alcohol use disorder through a specialized alcohol treatment program or the individuals primary care. Our approach to treating alcohol use disorder is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/108891.html" rel="external">"Alcohol use disorder: Treatment overview"</a>.)</p><p>Medically supervised withdrawal manages the patient through the withdrawal symptoms, but does not treat alcohol use disorder. Patients completing withdrawal who do not receive further treatment are at high risk of returning to regular heavy alcohol consumption [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H3220996689"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/114306.html" rel="external">"Society guideline links: Alcohol use disorders and withdrawal"</a>.)</p><p class="headingAnchor" id="H3682133766"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Need for treatment</strong> – We initiate management of alcohol withdrawal on most individuals with alcohol use disorder who have recently discontinued or sharply reduced their consumption. Exceptions include individuals who have been drinking for four weeks or less and those that exclusively binge drink three times or less per week. (See <a class="local">'Alcohol withdrawal: Diagnosis and need for treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Candidacy for ambulatory management</strong> – For all individuals who have been assessed for and found to need treatment for alcohol withdrawal, we assess for contraindications to ambulatory management. If none exist, we further assess for the presence of complex comorbidities or other unfavorable psychosocial factors for ambulatory management treatment. (See <a class="local">'Candidacy for ambulatory management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Contraindications to ambulatory management</strong> – Individuals with the following are at risk for severe withdrawal and are not treated in the ambulatory setting. If neither are present, we further assess for complex comorbidities, and other factors. (See <a class="local">'Contraindications to ambulatory management'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>History of withdrawal delirium or seizures</strong> – We manage individuals with a prior history of withdrawal delirium or alcohol withdrawal seizure in the inpatient setting. (See <a class="local">'History of withdrawal delirium or seizures'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Modest or severe symptom severity </strong>– We treat individuals a Clinical Institute Withdrawal Assessment for Alcohol, Revised (CIWA-Ar) score of &gt;15 in the inpatient setting. (See <a class="local">'Modest or severe symptom severity'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other reasons to avoid ambulatory management</strong> – If complex comorbidities are not present and if the psychosocial factors are favorable, we treat individuals who are not pregnant in the ambulatory setting. (See <a class="local">'Other reasons to avoid ambulatory management'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Complex comorbidities </strong>– We manage individuals with complex chronic medical or psychiatric comorbidity in the inpatient setting.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Psychosocial factors</strong> – We treat individuals with favorable psychosocial factors such as ability to monitor and administer medications reliably in the ambulatory setting.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Pregnancy </strong>– We check all appropriate individuals for pregnancy status. We treat all pregnant individuals in need of supervised withdrawal in the inpatient setting.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose regimens </strong>–<strong> </strong>We treat all individuals with a fixed-dose regimen in the ambulatory setting. We provide a limited amount symptom-triggered doses to take as needed. (See <a class="local">'Dose regimens and medication dispensing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choosing medication </strong>–<strong> </strong>An algorithm describes our practice for monitoring individuals being treated for alcohol withdrawal in the ambulatory setting  (<a class="graphic graphic_algorithm graphicRef138574" href="/z/d/graphic/138574.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild withdrawal (CIWA-Ar 10 to 15) </strong>– We suggest treatment of all individuals with a CIWA-Ar score of 10 to 15 with benzodiazepines as compared to other medications (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'For mild withdrawal (CIWA-Ar 10 to 15)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Very mild withdrawal (CIWA-Ar &lt;10) </strong>– We suggest treatment of all individuals with very mild symptoms of alcohol withdrawal (ie, CIWA-Ar &lt;10) with the anticonvulsant, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> as compared with other medications (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Very mild withdrawal (CIWA-Ar &lt;10)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – We are in contact with patients on a daily basis throughout supervised alcohol withdrawal. We refer individuals with seizures, delirium, worsening medical or psychiatric symptoms, increase in CIWA-Ar to &gt;15, or the use of more than one symptom-triggered dose in a 24-hour period, for inpatient treatment  (<a class="graphic graphic_algorithm graphicRef138558" href="/z/d/graphic/138558.html" rel="external">algorithm 2</a>). (See <a class="local">'Monitoring in the ambulatory setting'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent care</strong> – We offer explicit plans for follow-up maintenance treatment for alcohol use disorder during the supervised withdrawal. Individuals completing withdrawal who do not receive further treatment are at high risk of returning to regular heavy alcohol consumption. (See <a class="local">'Transition to maintenance treatment for alcohol use disorder'</a> above.)</p><p></p><p class="headingAnchor" id="H2941015353"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Richard Saitz, MD, MPH, FACP, DFASAM (deceased), Joseph R Volpicelli, MD, PhD, and Scott A Teitelbaum, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Goodson CM, Clark BJ, Douglas IS. Predictors of severe alcohol withdrawal syndrome: a systematic review and meta-analysis. Alcohol Clin Exp Res 2014; 38:2664.</a></li><li><a class="nounderline abstract_t">Turner RC, Lichstein PR, Peden JG Jr, et al. Alcohol withdrawal syndromes: a review of pathophysiology, clinical presentation, and treatment. J Gen Intern Med 1989; 4:432.</a></li><li><a class="nounderline abstract_t">Schuckit MA. Recognition and management of withdrawal delirium (delirium tremens). N Engl J Med 2014; 371:2109.</a></li><li><a class="nounderline abstract_t">McKeon A, Frye MA, Delanty N. The alcohol withdrawal syndrome. J Neurol Neurosurg Psychiatry 2008; 79:854.</a></li><li><a class="nounderline abstract_t">Sullivan JT, Sykora K, Schneiderman J, et al. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 1989; 84:1353.</a></li><li><a class="nounderline abstract_t">Foy A, McKay S, Ling S, et al. Clinical use of a shortened alcohol withdrawal scale in a general hospital. Intern Med J 2006; 36:150.</a></li><li><a class="nounderline abstract_t">Schuckit MA, Danko GP, Smith TL, et al. A 5-year prospective evaluation of DSM-IV alcohol dependence with and without a physiological component. Alcohol Clin Exp Res 2003; 27:818.</a></li><li><a class="nounderline abstract_t">Collins MN, Burns T, van den Berk PA, Tubman GF. A structured programme for out-patient alcohol detoxification. Br J Psychiatry 1990; 156:871.</a></li><li><a class="nounderline abstract_t">Soyka M, Horak M. Outpatient alcohol detoxification: implementation efficacy and outcome effectiveness of a model project. Eur Addict Res 2004; 10:180.</a></li><li><a class="nounderline abstract_t">Wiseman EJ, Henderson KL, Briggs MJ. Outcomes of patients in a VA ambulatory detoxification program. Psychiatr Serv 1997; 48:200.</a></li><li><a class="nounderline abstract_t">Hayashida M, Alterman AI, McLellan AT, et al. Comparative effectiveness and costs of inpatient and outpatient detoxification of patients with mild-to-moderate alcohol withdrawal syndrome. N Engl J Med 1989; 320:358.</a></li><li><a class="nounderline abstract_t">Elholm B, Larsen K, Hornnes N, et al. Alcohol withdrawal syndrome: symptom-triggered versus fixed-schedule treatment in an outpatient setting. Alcohol Alcohol 2011; 46:318.</a></li><li><a class="nounderline abstract_t">Wiseman EJ, Henderson KL, Briggs MJ. Individualized treatment for outpatients withdrawing from alcohol. J Clin Psychiatry 1998; 59:289.</a></li><li><a class="nounderline abstract_t">Amato L, Minozzi S, Vecchi S, Davoli M. Benzodiazepines for alcohol withdrawal. Cochrane Database Syst Rev 2010; :CD005063.</a></li><li><a class="nounderline abstract_t">Asplund CA, Aaronson JW, Aaronson HE. 3 regimens for alcohol withdrawal and detoxification. J Fam Pract 2004; 53:545.</a></li><li><a class="nounderline abstract_t">Mirijello A, D'Angelo C, Ferrulli A, et al. Identification and management of alcohol withdrawal syndrome. Drugs 2015; 75:353.</a></li><li><a class="nounderline abstract_t">Muncie HL Jr, Yasinian Y, Oge' L. Outpatient management of alcohol withdrawal syndrome. Am Fam Physician 2013; 88:589.</a></li><li><a class="nounderline abstract_t">Holbrook AM, Crowther R, Lotter A, et al. Meta-analysis of benzodiazepine use in the treatment of acute alcohol withdrawal. CMAJ 1999; 160:649.</a></li><li><a class="nounderline abstract_t">Soyka M, Kranzler HR, Hesselbrock V, et al. Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision. World J Biol Psychiatry 2017; 18:86.</a></li><li><a class="nounderline abstract_t">Perry EC. Inpatient management of acute alcohol withdrawal syndrome. CNS Drugs 2014; 28:401.</a></li><li><a class="nounderline abstract_t">Griffiths RR, Wolf B. Relative abuse liability of different benzodiazepines in drug abusers. J Clin Psychopharmacol 1990; 10:237.</a></li><li><a class="nounderline abstract_t">Griffiths RR, Johnson MW. Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry 2005; 66 Suppl 9:31.</a></li><li><a class="nounderline abstract_t">Sellers EM, Naranjo CA, Harrison M, et al. Diazepam loading: simplified treatment of alcohol withdrawal. Clin Pharmacol Ther 1983; 34:822.</a></li><li><a class="nounderline abstract_t">Miller WC Jr, McCurdy L. A double-blind comparison of the efficacy and safety of lorazepam and diazepam in the treatment of the acute alcohol withdrawal syndrome. Clin Ther 1984; 6:364.</a></li><li><a class="nounderline abstract_t">Wilson A, Vulcano BA. Double-blind trial of alprazolam and chlordiazepoxide in the management of the acute ethanol withdrawal syndrome. Alcohol Clin Exp Res 1985; 9:23.</a></li><li><a class="nounderline abstract_t">Whitfield CL, Thompson G, Lamb A, et al. Detoxification of 1,024 alcoholic patients without psychoactive drugs. JAMA 1978; 239:1409.</a></li><li><a class="nounderline abstract_t">Erstad BL, Cotugno CL. Management of alcohol withdrawal. Am J Health Syst Pharm 1995; 52:697.</a></li><li><a class="nounderline abstract_t">Longo LP, Campbell T, Hubatch S. Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention. J Addict Dis 2002; 21:55.</a></li><li><a class="nounderline abstract_t">Myrick H, Malcolm R, Randall PK, et al. A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. Alcohol Clin Exp Res 2009; 33:1582.</a></li><li><a class="nounderline abstract_t">Stock CJ, Carpenter L, Ying J, Greene T. Gabapentin versus chlordiazepoxide for outpatient alcohol detoxification treatment. Ann Pharmacother 2013; 47:961.</a></li><li><a class="nounderline abstract_t">Markowitz JS, Finkenbine R, Myrick H, et al. Gabapentin abuse in a cocaine user: implications for treatment? J Clin Psychopharmacol 1997; 17:423.</a></li><li><a class="nounderline abstract_t">Reccoppa L, Malcolm R, Ware M. Gabapentin abuse in inmates with prior history of cocaine dependence. Am J Addict 2004; 13:321.</a></li><li><a class="nounderline abstract_t">Victorri-Vigneau C, Guerlais M, Jolliet P. Abuse, dependency and withdrawal with gabapentin: a first case report. Pharmacopsychiatry 2007; 40:43.</a></li><li><a class="nounderline abstract_t">Pittenger C, Desan PH. Gabapentin abuse, and delirium tremens upon gabapentin withdrawal. J Clin Psychiatry 2007; 68:483.</a></li><li><a class="nounderline abstract_t">Del Paggio D. Psychotropic medication abuse in correctional facilities. Bay Area Psychopharmacology Newsletter 2005; 8:1.</a></li><li><a class="nounderline abstract_t">Feldman DJ, Pattison EM, Sobell LC, et al. Outpatient alcohol detoxification: initial findings on 564 patients. Am J Psychiatry 1975; 132:407.</a></li><li><a class="nounderline abstract_t">Abbott PJ, Quinn D, Knox L. Ambulatory medical detoxification for alcohol. Am J Drug Alcohol Abuse 1995; 21:549.</a></li><li><a class="nounderline abstract_t">Minozzi S, Amato L, Vecchi S, Davoli M. Anticonvulsants for alcohol withdrawal. Cochrane Database Syst Rev 2010; :CD005064.</a></li><li><a class="nounderline abstract_t">Bonnet U, Hamzavi-Abedi R, Specka M, et al. An open trial of gabapentin in acute alcohol withdrawal using an oral loading protocol. Alcohol Alcohol 2010; 45:143.</a></li><li><a class="nounderline abstract_t">Mariani JJ, Rosenthal RN, Tross S, et al. A randomized, open-label, controlled trial of gabapentin and phenobarbital in the treatment of alcohol withdrawal. Am J Addict 2006; 15:76.</a></li><li><a class="nounderline abstract_t">Mayo-Smith MF. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA 1997; 278:144.</a></li><li><a class="nounderline abstract_t">Lai JY, Kalk N, Roberts E. The effectiveness and tolerability of anti-seizure medication in alcohol withdrawal syndrome: a systematic review, meta-analysis and GRADE of the evidence. Addiction 2022; 117:5.</a></li><li><a class="nounderline abstract_t">Malcolm R, Myrick H, Roberts J, et al. The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial. J Gen Intern Med 2002; 17:349.</a></li><li><a class="nounderline abstract_t">Stuppaeck CH, Pycha R, Miller C, et al. Carbamazepine versus oxazepam in the treatment of alcohol withdrawal: a double-blind study. Alcohol Alcohol 1992; 27:153.</a></li><li><a class="nounderline abstract_t">Schik G, Wedegaertner FR, Liersch J, et al. Oxcarbazepine versus carbamazepine in the treatment of alcohol withdrawal. Addict Biol 2005; 10:283.</a></li><li><a class="nounderline abstract_t">Martinotti G, di Nicola M, Frustaci A, et al. Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi-centre, randomized, single-blind comparison trial. Addiction 2010; 105:288.</a></li><li><a class="nounderline abstract_t">Richter C, Hinzpeter A, Schmidt F, et al. Levetiracetam for the treatment of alcohol withdrawal syndrome: a multicenter, prospective, randomized, placebo-controlled trial. J Clin Psychopharmacol 2010; 30:720.</a></li><li><a class="nounderline abstract_t">Müller CA, Schäfer M, Schneider S, et al. Efficacy and safety of levetiracetam for outpatient alcohol detoxification. Pharmacopsychiatry 2010; 43:184.</a></li><li><a class="nounderline abstract_t">Youland KM, Miller RF, Mahoney LJ, et al. Levetiracetam as adjunctive therapy for acute alcohol withdrawal syndrome in hospitalized patients. J Clin Psychopharmacol 2014; 34:704.</a></li><li><a class="nounderline abstract_t">Lum E, Gorman SK, Slavik RS. Valproic acid management of acute alcohol withdrawal. Ann Pharmacother 2006; 40:441.</a></li><li><a class="nounderline abstract_t">Addolorato G, Leggio L, Abenavoli L, et al. Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam. Am J Med 2006; 119:276.e13.</a></li><li><a class="nounderline abstract_t">Muzyk AJ, Fowler JA, Norwood DK, Chilipko A. Role of α2-agonists in the treatment of acute alcohol withdrawal. Ann Pharmacother 2011; 45:649.</a></li><li><a class="nounderline abstract_t">Liu J, Wang LN. Baclofen for alcohol withdrawal. Cochrane Database Syst Rev 2015; :CD008502.</a></li><li><a class="nounderline abstract_t">Leone MA, Vigna-Taglianti F, Avanzi G, et al. Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses. Cochrane Database Syst Rev 2010; :CD006266.</a></li><li><a class="nounderline abstract_t">Charness ME, Simon RP, Greenberg DA. Ethanol and the nervous system. N Engl J Med 1989; 321:442.</a></li><li><a class="nounderline abstract_t">Cook CC. Prevention and treatment of Wernicke-Korsakoff syndrome. Alcohol Alcohol Suppl 2000; 35:19.</a></li><li><a class="nounderline abstract_t">Blondell RD. Ambulatory detoxification of patients with alcohol dependence. Am Fam Physician 2005; 71:495.</a></li></ol></div><div id="topicVersionRevision">Topic 7801 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25346507" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Predictors of severe alcohol withdrawal syndrome: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2677272" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Alcohol withdrawal syndromes: a review of pathophysiology, clinical presentation, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25427113" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Recognition and management of withdrawal delirium (delirium tremens).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17986499" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The alcohol withdrawal syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2597811" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16503949" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinical use of a shortened alcohol withdrawal scale in a general hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12766627" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A 5-year prospective evaluation of DSM-IV alcohol dependence with and without a physiological component.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2207519" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A structured programme for out-patient alcohol detoxification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15367820" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Outpatient alcohol detoxification: implementation efficacy and outcome effectiveness of a model project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9021850" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Outcomes of patients in a VA ambulatory detoxification program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2913493" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Comparative effectiveness and costs of inpatient and outpatient detoxification of patients with mild-to-moderate alcohol withdrawal syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21414950" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Alcohol withdrawal syndrome: symptom-triggered versus fixed-schedule treatment in an outpatient setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9671340" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Individualized treatment for outpatients withdrawing from alcohol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20238336" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Benzodiazepines for alcohol withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15251094" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : 3 regimens for alcohol withdrawal and detoxification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25666543" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Identification and management of alcohol withdrawal syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24364635" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Outpatient management of alcohol withdrawal syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10101999" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Meta-analysis of benzodiazepine use in the treatment of acute alcohol withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28006997" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24781751" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Inpatient management of acute alcohol withdrawal syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1981067" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Relative abuse liability of different benzodiazepines in drug abusers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16336040" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6641099" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Diazepam loading: simplified treatment of alcohol withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6722863" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A double-blind comparison of the efficacy and safety of lorazepam and diazepam in the treatment of the acute alcohol withdrawal syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3887964" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Double-blind trial of alprazolam and chlordiazepoxide in the management of the acute ethanol withdrawal syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/633543" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Detoxification of 1,024 alcoholic patients without psychoactive drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7627738" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Management of alcohol withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11916372" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19485969" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23780805" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Gabapentin versus chlordiazepoxide for outpatient alcohol detoxification treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9315994" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Gabapentin abuse in a cocaine user: implications for treatment?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15370954" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Gabapentin abuse in inmates with prior history of cocaine dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17327964" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Abuse, dependency and withdrawal with gabapentin: a first case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17388722" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Gabapentin abuse, and delirium tremens upon gabapentin withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Psychotropic medication abuse in correctional facilities</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1119592" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Outpatient alcohol detoxification: initial findings on 564 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8561102" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Ambulatory medical detoxification for alcohol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20238337" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Anticonvulsants for alcohol withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20019070" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : An open trial of gabapentin in acute alcohol withdrawal using an oral loading protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16449096" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A randomized, open-label, controlled trial of gabapentin and phenobarbital in the treatment of alcohol withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9214531" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33822427" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The effectiveness and tolerability of anti-seizure medication in alcohol withdrawal syndrome: a systematic review, meta-analysis and GRADE of the evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12047731" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1524606" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Carbamazepine versus oxazepam in the treatment of alcohol withdrawal: a double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16109591" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Oxcarbazepine versus carbamazepine in the treatment of alcohol withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20078487" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi-centre, randomized, single-blind comparison trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21105289" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Levetiracetam for the treatment of alcohol withdrawal syndrome: a multicenter, prospective, randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20503149" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Efficacy and safety of levetiracetam for outpatient alcohol detoxification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25144138" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Levetiracetam as adjunctive therapy for acute alcohol withdrawal syndrome in hospitalized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16507623" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Valproic acid management of acute alcohol withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16490478" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21521867" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Role ofα2-agonists in the treatment of acute alcohol withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25836263" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Baclofen for alcohol withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20166080" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2668759" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Ethanol and the nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11304070" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Prevention and treatment of Wernicke-Korsakoff syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15712624" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Ambulatory detoxification of patients with alcohol dependence.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
